Genentech letter warns of stroke risk with ranibizumab

March 1, 2007

South San Francisco-Genentech Inc. is advising ophthalmologists that it is seeing a slightly higher incidence of stroke among patients using the 0.5-mg dose of its ranibizumab injection (Lucentis) to treat wet age-related macular degeneration (AMD).